Pfizer Reports Positive Phase II Trial of BRAF, MEK Inhibitor Combo in Multiple Myeloma
NEW YORK – In a small Phase II trial evaluating Pfizer’s encorafenib (Braftovi) and binimetinib (Mektovi), the majority of heavily pretreated, refractory multiple myeloma patients with BRAF V600 mutations saw their tumors shrink on the combination regimen, researchers reported at the American Society of Hematology’s annual meeting on Saturday.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Published at Mon, 07 Dec 2020 03:56:15 +0000